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Objective: In the present work a cardiovascular simulator designed both for clinical and training use is
presented.
Method: The core of the simulator is a lumped parameter model of the cardiovascular system provided
with several modules for the representation of baroreﬂex control, blood transfusion, ventricular assist
device (VAD) therapy and drug infusion. For the training use, a Pre-Set Disease module permits to select
one or more cardiovascular diseases with a different level of severity. For the clinical use a Self-Tuning
module was implemented. In this case, the user can insert patient’s speciﬁc data and the simulator will
automatically tune its parameters to the desired hemodynamic condition.
The simulator can be also interfaced with external systems such as the Specialist Decision Support
System (SDSS) devoted to address the choice of the appropriate level of VAD support based on the clinical
characteristics of each patient.
Results: The Pre-Set Disease module permits to reproduce a wide range of pre-set cardiovascular diseases
involving heart, systemic and pulmonary circulation. In addition, the user can test different therapies as
drug infusion, VAD therapy and volume transfusion. The Self-Tuning module was tested on six different
hemodynamic conditions, including a VAD patient condition. In all cases the simulator permitted to
reproduce the desired hemodynamic condition with an error < 10%.
Conclusions: The cardiovascular simulator could be of value in clinical arena. Clinicians and students can
utilize the Pre-Set Diseases module for training and to get an overall knowledge of the pathophysiology of
common cardiovascular diseases. The Self-Tuning module is prospected as a useful tool to visualize
patient’s status, test different therapies and get more information about speciﬁc hemodynamic
conditions. In this sense, the simulator, in conjunction with SDSS, constitutes a support to clinical
decision – making.
 2015 Elsevier Inc. All rights reserved.diastolic
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Due to the complexity of the cardiovascular system, computa-
tional and hydraulic simulators are becoming nowadays
more and more appreciated to get an overall understanding of
different pathophysiological conditions. In general, the use of
simulators for training and educational purposes is growing, so
that open source applications [1] or even mobile applications have
been developed [2].Simulators can be either computational [3,4] or mock systems,
devoted to the testing and training of speciﬁc applications as per-
fusion techniques and ventricular assist devices (VADs1) [5–7].a p
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are devoted either to the test of new devices or to the study of
patient–device interaction [8–10]. In addition, simulators can also
be used as a support to clinical decision – making. In this case, the
model is tailored to a patient’s data to reproduce the corresponding
hemodynamic condition. Then, one or more clinical therapies or
interventions can be simulated to check patient’s reaction and intro-
duce possible improvements [11].
To be suitable for both training and clinical use, these models
have to meet the requirements of high ﬂexibility, low execution
time and intuitive user interface.
The present work is focused on developing a cardiovascular
simulator (CVS) for training and clinical use. CVS is developed as
a modular system offering a wide range of scenarios dedicated to
speciﬁc tasks and applications both for the training and the clinical
use. For the training use, the simulator can reproduce a wide range
of Pre-Set Diseases and can provide the hemodynamic outcome to
the user. Concerning the clinical use, the user feeds CVS with
patient’s speciﬁc data and the simulator performs a Self-Tuning
procedure to reproduce the desired patient’s condition. In addition,
CVS permits to simulate several therapeutical interventions as
drug infusion, ventricular mechanical assistance device and blood
loss or infusion.2. Materials and methods
2.1. Cardiovascular simulator overview
The cardiovascular simulator was developed under LabVIEW™
(National Instruments, Austin, TX, USA) and has a modular struc-
ture (see Fig. A1 for further details). The core of the simulator is
the numerical circulatory model, integrated with several modules,
each of them devoted to a speciﬁc application. Some of the
modules of the simulator were already described in previous works
[12,13]. Therefore a brief overview of the already published
modules and a detailed description of the new ones are provided
in this manuscript.
The user interface was also developed in LabVIEW™ (see
Fig. A2) and it is divided into four windows. The main window
contains the general interface providing pressure waveforms as
well as left and right ventricular pressure–volume loops (PV loops).
In addition, mean values of the main pressures and ﬂows are
calculated and presented at the end of each simulated cardiac
cycle. This interface includes also some control buttons to
activate/deactivate some applications of the simulator.
The other three interfaces are devoted to: Preset and Random
diseases modules, Self-Tuning module and therapies module (this
latter including VAD, drug administration and blood transfusion).
These three windows can be opened or closed from the main
interface, according to user needs.
To improve the readability of the present manuscript, it is useful
to specify that authors use the term ‘‘parameters’’ to indicate
CVS data as: resistances, compliances, inertances, elastances,
zero-pressure ﬁlling volumes and total blood volume. The term
‘‘variables’’ is used to indicate CVS outputs like ﬂows and pressures.2.2. Cardiovascular module
The cardiovascular module is a lumped parameter model
providing a representation of left and right hearts, systemic and
pulmonary circulations. A detailed description of it was already
provided in [12]. The systemic circulation is split into: ascending
and descending aorta, upper body, renal, splanchnic, lower limbs
circulatory subsystems. Both sections of the aorta are represented
as a Windkessel model. The other vascular districts are representedby arterial resistance, compliance, vascular tone and venous resis-
tance [12,14]. The pulmonary circulation is also split into arterial
and venous sections, each of them represented by a Windkessel
model [12]. Atria are represented as compliances while for both
ventricles the time-varying elastance model is used [15]. The ﬁlling
characteristic of the ventricle is represented with a series of
exponential functions [12]. A complete list of all the parameters
and their values used to simulate a standard subject is reported
in Table 1. These values refer to a standard healthy subject of
75–80 kg, therefore they will be indicated in the text as ‘‘reference’’
values (with subscript ref).
2.3. Baroreﬂex module
Baroreﬂex model was mainly taken from Ursino [16] and fur-
ther adapted by the authors [12]. The model compares the actual
aortic pressure with a set-point value. This difference is used to
calculate both afferent and efferent nervous pathways. These latter
are split into sympathetic and vagal pathways regulating the
cardiovascular parameters through a ﬁrst order system. More in
detail, the sympathetic nerve activity controls heart rate, ventricu-
lar contractility, arterial peripheral resistance and venous tone. The
vagal nerve activity controls only heart rate.
2.4. Blood volume control module
Blood volume can be either tailored to the patient’s weight or
changed manually by the user. In the latter case, the user can spec-
ify the rate and the total amount of blood to be infused/withdrawn
and observe the reaction in terms of hemodynamics output.
2.5. VAD module
The VAD module includes a representation of three types of
ventricular assist devices: HeartMate II (Thoratec Corporation,
Pleasanton, CA, USA), HeartWare and CircuLite Synergy
Micropump (HeartWare, Framingham, MA, USA). For each VAD,
the relationship between pump head and ﬂow is represented
according to a polynomial equation:
DP ¼ a  Q2 þ b  Q þ c ð1Þ
where Q is the VAD ﬂow and DP is the pressure drop across the
VAD. The parameters a, b, c were estimated from VAD
pressure-ﬂow static characteristics and their values change
according to the VAD speed selected by the user. As HeartMate II
and HeartWare have an apical insertion, DP will be the pressure
drop between the left ventricular pressure and aortic pressure. In
the case of CircuLite Synergy Micropump, the DP will be the pres-
sure drop between the left atrial pressure and the aortic pressure.
2.6. Drug infusion module
This module is an extension of Gopinath model [17] and was
already described in [13]. The user can select the rate of infusion
and then the model provides the concentration of the drug in each
vascular compartment as well as its rate of consumption (accord-
ing to drug half-life) as output. The drug module provides a
description of the main effects of sodium nitroprusside (SNP) on
systemic vascular resistance.
2.7. Preset diseases module
This module is conceived to provide users with a speciﬁc interface
where one or more pathological conditions can be activated. The user
can activate one or more diseases and also select the level of severity.
Table 1
Cardiovascular parameters – reference values.
Symbol Parameter Default value
Left (Right) ventricle
LV0ref/RV0ref Left/Right rest volume 5/5 cm
3 [15]
Emaxlref/Emaxrref Left/Right systolic Elastance 2.5/1.01 mmHg/cm
3 [12]
Edlref/Edrref Left/Right diastolic function
al-b-cl-dl 0.035–0.035–0.03–0.3
ar-br-cr-dr 0.042–0.042–0.045–0.3
Rliref/Rriref Left/Right atrioventricular valve resistance 0.02/0.02 mmHg s/cm3 [12]
Rloref/Rroref Aortic/Pulmonary valve resistance 0.02/0.02 mmHg s/cm3 [12]
Ascending aorta and aortic arch
Ra1ref Resistance 0.01 mmHg s/cm3 [12]
La1ref Inertance 5  105 mmHg s2/cm3 [4]
Ca1ref Compliance 0.8 cm
3/mmHg
Va10ref Zero-pressure ﬁlling volume 400 cm3
Descending aorta
Ra2ref Resistance 0.07 mmHg s/cm3 [12]
La2ref Inertance 5  105 mmHg s2/cm3 [4]
Ca2ref Compliance 0.6 cm
3/mmHg [12]
Va20ref Zero-pressure ﬁlling volume 315 cm3
Upper body circulation
Rubaref Arterial resistance 3.9 mmHg s/cm
3 [14]
Rubvref Venous resistance 0.23 mmHg s/cm3 [14]
Cubref Compliance 8 cm
3/mmHg [14]
Vub0ref Zero-pressure ﬁlling volume 650 cm
3 [14]
Kidney circulation
Rkidaref Arterial resistance 4.1 mmHg s/cm
3[14]
Rkidvref Venous resistance 0.3 mmHg s/cm3 [14]
Ckidref Compliance 15 cm
3/mmHg [14]
Vkid0ref Zero-pressure ﬁlling volume 150 cm
3 [14]
Splanchnic circulation
Rsparef Arterial resistance 3.0 mmHg s/cm
3 [14]
Rspvref Venous resistance 0.18 mmHg s/cm3 [14]
Cspref Compliance 55 cm
3/mmHg [14]
Vsp0ref Zero-pressure ﬁlling volume 1300 cm
3 [14]
Lower limbs circulation
Rllaref Arterial resistance 3.6 mmHg s/cm
3[14]
Rllvref Venous resistance 0.3 mmHg s/cm3 [14]
Cllref Compliance 19 cm
3/mmHg [14]
Vll0ref Zero-pressure ﬁlling Volume 350 cm
3 [14]
Superior Vena Cava
Rsupref Resistance 0.06 mmHg s/cm3 [14]
Csupref Compliance 15 cm
3/mmHg [14]
Vsup0ref Zero-pressure ﬁlling volume 10 cm
3 [14]
Lower Vena Cava
Rinfref Resistance 0.015 mmHg s/cm3 [14]
Cinfref Compliance 27 cm
3/mmHg [14]
Vinf0ref Zero-pressure ﬁlling volume 325 cm
3[14]
Pulmonary arterial circulation
Rcpref Charact. resistance 0.005 mmHg s/cm3 [4]
Capref Arterial compliance 3 cm3/mmHg [14]
Rapref Arterial resistance 0.075 mmHg s/cm3 [4]
Lapref Arterial inertance 3.6  105 mmHg s2/cm3 [4]
Vap0ref Zero-pressure ﬁlling volume 90 cm
3 [14]
Pulmonary venous circulation
Rvpref Venous resistance 0.005 mmHg s/cm3 [4]
Cvpref Venous compliance 3 cm3/mmHg [14]
Vap0ref Zero-pressure ﬁlling volume 580 cm
3 [14]
Total circulation
TOTVolref Total blood volume 5425 cm3
BodyWeightref Total body weight 77.5 kg
Baroreﬂex control
PasSETref Baroreﬂex set point pressure 98 mmHg
Underlined parameters are changed during the Self-Tuning procedure.
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opathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, right
heart failure, aortic regurgitation, aortic stenosis, mitral regurgitation,
systemic hypertension, pulmonary hypertension. Diseases not com-
patible each other (i.e. dilated andhypertrophic cardiomyopathy) can-
not be activated simultaneously.2.8. Random Disease module
As a second option, the user can activate the Random Disease
module, meaning the simulator will automatically generate one
or more diseases in a blind modality and provide to the user the
resulting hemodynamic condition. The idea behind this is that
the user does not know in advance the combination of diseases
generated by the simulator, so he/she will try to disclose the hemo-
dynamic condition provided by the simulator, adopting the proper
therapeutic actions.
Parameters values used to simulate different diseases are
reported in Table 2. Some comments about the choice of parame-
ters are reported in the discussion section.2.9. Self-Tuning module
This module is devoted to the representation of a patient’s
speciﬁc hemodynamic condition. When activated, a dedicated
window appears where the user can insert the patient’s data
that will be used as target data by the simulator. More in detail,
target data are used to calculate model parameters and to per-
form the Self-Tuning procedure. At the end of the operation,
the simulated data are compared with the corresponding target
data. If they differ less than the tolerance level, the model is
tuned and the procedure is ended (the tolerance level is the
maximum acceptable difference between the target data and
the simulated one).
The Self-Tuning procedure requires as input the following
haemodynamic data (they are marked with ‘‘⁄’’ to indicate they
are the patient’s speciﬁc data): heart rate (HR⁄) – BodyWeight⁄ –
Height⁄ – mean systemic arterial pressure (AOP⁄) – systolic
systemic arterial pressure (AOPsys⁄) – diastolic systemic arterial
pressure (AOPdias⁄) – left atrial pressure (LAP⁄) – pulmonary arte-
rial pressure (PAP⁄) – right atrial pressure (RAP⁄) – left ventricular
end-systolic (end-diastolic) volume LVes⁄ (LVed⁄), duration of
diastole within a heart cycle (Tdecay⁄).Table 2
Preset diseases – parameters values.
Disease Param. Values
Mild
Ischemic cardiom. Els 1.5
LV0 25
Dilated cardiom. al-bl-cl-dl 0.03–0.03–0.03–0
Hypertrophic cardiom. al-bl-cl-dl 0.05–0.05–0.035–
Right heart failure Emaxr 0.9
RV0 15
Aortic regurgitation Rloinv 500
Aortic stenosis Rli 40
Mitral regurgitation Rliinv 500
Systemic hypertension Ca1 0.06
Ca2 0.78
Ruba 5.07
Rkida 5.33
Rspa 3.9
Rlla 4.68
Pulmonary hypertension Rap 0.1
Values refer to 3 different levels of severity of the disease.The simulator performs the Self-Tuning also in case of VAD
assistance, both for apical and atrio–aortic connections. For apical
VAD, the user will have to insert also the VAD ﬂow (VADﬂow⁄)
and patient total cardiac output (CO⁄). The difference
CO⁄–VADﬂow⁄ will correspond to the left ventricular output ﬂow
in the aorta (Qol⁄).
For atrio–aortic assistance, the user will have to insert only
VADﬂow⁄. In this case, in fact, Qol⁄ can be estimated from ventric-
ular volumes (LVes⁄ and LVed⁄) and from HR⁄.
The Self-Tuning is a two steps procedure, they are described in
the following paragraphs.
2.9.1. STEP 1
Initially, the following volumes are estimated from the target
data:
 Total blood volume (TOTVol⁄): estimated according to the ‘‘nor-
mal’’ ratio blood volume/weight of 75 cm3/kg [18].
 LVes⁄ and LVed⁄: estimated on the basis of echocardiographic
measurements. If the ventricular diameter alone is available,
the ventricular volume is estimated using the Teicholz
formula:LVed ¼ 7  ðDiamedÞ3=ð2:4þ DiamedÞ
LVes ¼ 7  ðDiamesÞ3=ð2:4þ DiamesÞ
ð2Þ
With Diames (Diamed) left ventricular at end-systolic
(end-diastolic) diameter.
 Left ventricular zero pressure ﬁlling volume (LV0): a ﬁrst pre-
liminary estimation is done using an empirical equation
obtained from [19]. Data concerning LVes and LV0 taken from
[19] were used to perform a linear regression analysis. The
resulting equation is LV0 = 1.344  LVes-138.2.
 Left ventricular end-systolic elastance (Emaxl): estimated on the
basis of the Suga–Sagawa model [15] using as input data LV0
previously estimated, LVes⁄ and AOPsys⁄ (if the peak systolic
ventricular pressure is not available).
 Left ventricular diastolic function (Edl): a linearization of the
ﬁlling characteristic is performed. The diastolic line is calculated
using the ratio between the end-diastolic left ventricular pres-
sure and volume.
 Total pulmonary resistance (Rptot) and total systemic resistance
(Rstot): estimated as the ratio between the pressure drop across
the circulation itself and CO⁄.Moderate Severe
1 0.5
50 75
.3 0.03–0.028–0.03–0.3 0.0025–0.025–0.03–0.3
0.3 0.06–0.06–0.350.3 0.07–0.07–0.35–0.3
0.7 0.4
30 45
300 150
80 120
300 150
0.45 0.25
0.3 0.15
6.24 7.41
6.56 7.79
4.8 5.7
5.76 6.84
0.14 0.2
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and descending aorta (Ca2): they are estimated on the basis of
the aortic pressure decay method [20]. The formula used is
reported in Fig. A3 and it involves the following parameters:
AOPsys⁄, AOPdias⁄, Rstot (calculated as indicated above) and
Tdecay⁄. AOPsys⁄ is an approximation of AOP⁄ at the dicrotic
notch (as invasive pressure measurements are not always avail-
able). If electrocardiographic data are not available and there-
fore Tdecay⁄ is not measured, the model estimates it
automatically on the basis of HR⁄, according to the following
empirical formula derived from [21]:S=D ¼ HR2  0:0001 HR  0:017þ 1:297
Tdecay ¼ 60=HR  ð1þ S=DÞ
ð3Þ
where S/D is the systole to diastole duration ratio.
 Arterial peripheral resistances in speciﬁc circulatory districts as
upper body (Ruba), kidneys (Rkida), splanchnic (Rspa), lower
limbs (Rlla): they are estimated on the basis of Rstot and consid-
ering a repartition of total cardiac output of 23% for upper body,
22% for kidneys, 30% for splanchnic circulation and 25% for
lower limbs [14].
 Venous systemic resistances (Rubv, Rkidv, Rspv, Rllv): their val-
ues are taken from [14].
 Venous compliances (Cub, Ckid, Csp, Cll, Cinf, Csup): their refer-
ence values, reported in Table 1, are characterized according
to [14] that refer to a subject of 75–80 kg. The resulting refer-
ence total venous systemic compliance is 139 cm3/mmHg that
divided by body weight provides a ratio of 1.80 cm3/
(mmHg kg)1. This value is in agreement with the ratio of
2.3 ± 0.7 cm3/(mmHg kg)1 reported by Takatsu et al. [22]. On
the basis of this relationship present in the literature, the
venous compliance is tuned according to patient’s body weight
as it follows:Ci ¼ Ciref  BodyWeight=BodyWeightref ð4Þ
 Where Ci is the venous compliance of the ith vascular district at
patient’s speciﬁc body weight (BodyWeight), Ciref is the corre-
sponding value at the reference BodyWeightref of 77.5 kg (see
Table 1).
 Venous tones (Vaa0, Vabd0, Vub0, Vkid0, Vsp0, Vll0, Vsup0, Vinf0,
Vap0, Vvp0) are estimated on the basis of a reference value for
each of them (see Table 1) and then adapting their values
according to BodyWeight⁄ as it follows.Vi ¼ Viref  BodyWeight=BodyWeightref ð5Þ
2.9.2. STEP 2
The recursive procedure is executed and: on the basis of the
comparison between target and simulated data, some parameters
are further tuned. These parameters are: TOTVol, Emaxl, Emaxr,
Edr and LV0. Parameters are usually changed as it follows:
Pa ¼ Pp þ DViP þ DViiP þ   
DViP ¼ ðVi ViÞ  KVi!P=Vi
ð6Þ
where Pa (Pp) is the actual (previous) value of the generic parameter
P, DViP is the variation of P due to the variable Vi. The variation DViP
is calculated on the basis of the target data (Vi*) and the value Vi
obtained from the simulation. In addition the coefﬁcient KVi?P is
used to regulate the weight with which a variable affects a
parameter.
At the end of the tuning procedure, an overall check of all the
variables is made. The procedure for this is the following:Vim ¼ ð100 tolÞ  Vi=100
ViM ¼ ð100þ tolÞ  Vi=100
if Vim < Vi < ViM
 
model is tuned else repeat step 2
ð7Þ
where Vi is the value of the variable obtained from the simulation.
Vi*M (Vi*m) is the upper (lower) value that is accepted for Vi, tol is the
tolerance (usually a tol = 10 is considered). If all variables Vi are
within the range, then the simulation is considered acceptable
and the Self-Tuning procedure is stopped. If the simulated variable
is still too different from the target data, a new tuning loop is exe-
cuted. A block diagram of the Self-Tuning procedure is reported in
the Appendix A section (Fig. A3).
2.10. Specialist Decision Support System (SDSS)
The SDSS is a Web 2.0 application (based on HTML5, CSS and
Ajax) connectable to the CVS [23] and developed in the frame of
SensorART EU project [24,25]. The SDSS provides advanced func-
tionalities that emphasize user-generated content, usability, and
interoperability through a standard Web browser [26]. Thus, the
specialists are able to have access from multiple locations utilizing
familiar procedures and intuitive interfaces. The SDSS consists of a
set of tools, and enables authorized access to the corresponding
functionalities. Rather than addressing a single issue, it provides
specialists with advanced data-driven techniques and
expert-knowledge techniques and is composed of the following
tools:
 Association rules tool: It adopts intelligent data-mining tech-
niques in order to enable the specialists to easily search for
trends and shifts, as well as identify interesting interrelations
and extract new knowledge from multiple and heterogeneous
data.
 Statistics tool: It provides to the specialists a complete set of
statistics tools in order to analyze and interpret patient data;
examine the results of previous therapeutic regimens, and
obtain quantitative explanations of the observations.
 Weaning tool: It combines expert knowledge with multivariate
statistical analysis, in order to support the specialists on the
weaning decision. It enables them to create and maintain expert
models (in the form of clinical rules related to the overall health
and cardiovascular status of a subject), and run these models
against their patients. Data driven techniques are also employed
in order to enhance the models and effectively exploit past
patient data.
 Treatment tool: It includes several acknowledged risk scores and
models allowing the specialists to build risk proﬁles for their
patients, take rapid decisions, and foresee possible complica-
tions after VAD implant.
 Speed Optimization Tool: Using simulated data from the Speed
Optimization Tool enables the specialists to investigate the
potential effect of different VAD speeds on important hemody-
namic variables, and determine an optimal pump speed that
maintains a safe physiological operating point, while providing
adequate cardiac output for the patient. This application was
already shown in [23].
3. Results
3.1. Pre-Set Diseases
In this section some examples of Pre-Set Diseases are shown.
The diseases activated on the simulator and the relative level of
severity are indicated in italic, for the corresponding parameters
values please refer to Table 2.
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shown. Data refer to left ventricular pressure–volume (PV) loops
in: (1) physiological condition, (2) severe post-ischemic car-
diomyopathy (severe ischemic cardiomyopathy + severe dilated
cardiomyopathy) causing an extreme dilation of the left
ventricle, (3) the previous pathological condition combined with
a moderate systemic hypertension, (4) severe hypertrophic
cardiomyopathy.
In Fig. 2 the PV loops of the cardiovascular model relative to
valve diseases simulation are shown. Data refer to: (1) moderate
post-ischemic cardiomyopathy (moderate ischemic cardiomyopa-
thy +moderate dilated cardiomyopathy), (2) condition at point 1
plus severe aortic regurgitation, (3) condition at point 1 plus severe
mitral regurgitation, (4) mild hypertrophic cardiomyopathy plus sev-
ere aortic stenosis.
In Fig. 3 the right ventricular PV loops are shown: (1) physiolog-
ical condition, (2) severe right heart failure and (3) condition at
point 2 plus a moderate pulmonary hypertension.0
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Fig. 1. Left ventricular PV loop in four different conditions: (1) physiological
condition, (2) severe ischemic cardiomyopathy + severe dilated cardiomyopathy,
(3) severe ischemic cardiomyopathy + severe dilated cardiomyopathy + moderate
hypertension, (4) severe hypertrophic cardiomyopathy. Dashed lines indicate the
end-systolic elastance and the diastolic function for each condition.
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Fig. 2. Left ventricular PV loops in four different conditions: (1) moderate ischemic
cardiomyopathy + moderate dilated cardiomyopathy, (2) moderate dilated car-
diomyopathy + moderate ischemic cardiomyopathy + severe aortic regurgitation,
(3) moderate ischemic cardiomyopathy + moderate ischemic cardiomyopa-
thy + severe mitral regurgitation, (4) mild hypertrophic cardiomyopathy + severe
aortic stenosis.3.2. Therapeutic interventions
As previously mentioned, therapeutic interventions mainly con-
cern VAD, drug infusion and blood volume control.
As an example, the effects of different VADs in a dilated left ven-
tricle, due to a severe degree of ischemic disease (severe ischemic
cardiomyopathy +moderate dilated cardiomyopathy), are provided
in Fig. 4. Results concern the effects of the three different numerical
models of VADs: HeartMate II, HeartWare in apical connection and
CircuLite Synergy Micropump in atrio–aortic connection. The
HeartMate II is activated at a speed of 10,500 rpm to provide a ﬂow
of 5.3 l/min, the HeartWare is activated at a speed of 2200 rpm to
provide a ﬂow of 4.6 l/min and the CircuLite Synergy Micropump
is activated at a speed of 24,000 rpm to provide a ﬂow of
3.6 l/min. In this latter case the CircuLite provides a partial support
so that the left ventricle is still contributing to the total cardiac out-
put with a ﬂow of 0.6 l/min.
The effects of blood transfusion and of sodium nitroprusside
(SNP) infusion are shown in Fig. 5. SNP was provided with a rate
of 3 lg/kg/min, while the total amount of blood transfused was
500 ml.0
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the effect of baroreﬂex control was considered (for more details
about this modules please refer to [13]).
Blood transfusion (condition 2a in Fig. 5) mainly affects
ventricular preload, resulting in an increment of LVed (from
141 cm3 in physiological condition to 164 cm3). As a conse-
quence, ventricular stroke volume increases as well (from
89 cm3 in physiological condition to 102 cm3 after blood
transfusion).
SNP administration (condition 3a in Fig. 5) provokes a systemic
vasodilation thus reducing the outﬂow pressure the left ventricle
has to overcome in systole (peak ventricular pressure of
131 mmHg in physiological condition vs. 118 mmHg after SNP).
As a consequence, the left ventricle can easier eject blood in the
aorta, so that stroke volumes increases from 86 cm3 in physiologi-
cal condition to 109 cm3 after SNP.Table 3
Hemodynamic data corresponding to conditions in Figs. 1–5.
Fig. 1 Left EF% LVes/LVed [cm3] CO [l/min] AOP
1 63 141/52 5.7 119/
2 20 281/225 3.6 73/4
3 16 290/244 2.9 82/6
4 61 89/34 3.5 74/5
Fig. 2 Left EF% – regurgitation fraction LVes/LVed [cm3] CO [l/min] AOP
1 33 224/150 4.7 99/6
2 45–56 264/146 3.4 95/4
3 59–57 243/106 3.8 80/5
4 60 120/48 4.6 95/6
Fig. 3 Right EF% RVes/RVed [cm3] CO [l/min] AOP
1 74 118/30 5.7 119/
2 33 123/82 4.2 91/6
3 29 129/91 3.0 68/4
Fig. 4 Qol/VADﬂow [l/min] LVes/LVed [cm3] CO [l/min] AOP
1 3.1/0 (EF% = 19) 253/206 3.1 64/4
2 0.6/3.6 237/227 4.2 75/7
3 0/4.6 226/194 4.6 82/7
4 0/5.3 201/168 5.3 93/9
Fig. 5 Left EF% LVes/LVed [cm3] CO [l/min] AOP
2a 62 164/62 6.6 143/
2b 63 150/55 6.1 126/
3a 70 155/46 7 103/
3b 70 157/47 7 111/If we consider the same experiments but including also the
baroreﬂex control (conditions 2b and 3b in Fig. 5), we observe
smaller changes of the PV loops, due to the action of both sympa-
thetic and parasympathetic nerves that try to keep homeostasis by
changing parameters as HR and Rstot. As for example during blood
infusion HR decreases from 65 bpm to 62 bpm to counteract the
increment of blood pressure. During SNP infusion the baroreﬂex
counteracts the vasodilation: without baroreﬂex control the decre-
ment of Rstot is 43%, while with the baroreﬂex control the total
decrement of Rstot is 36%.
Some additional data of the hemodynamic conditions shown in
Figs. 1–5 are summarized in Table 3.
3.3. Self-Tuning module
The veriﬁcation of the model Self-Tuning module was per-
formed using literature and clinical data. Different diseases have
been chosen, in order to test model performance in a wide range
of hemodynamic conditions. A list of these conditions is reported
in Table 4 with the relative hemodynamic data. They refer to:
Left ventricular Ischemic Cardiomyopathy (LIC-CASE 1), Left ven-
tricular Dilated Cardiomyopathy (LDC-CASE 2, LDC-CASE 3,
LDC-CASE 4), Right Ventricular Dysfunction (RVD-CASE 5).
Furthermore, a VAD implanted patient condition was considered
(CircuLite-CASE 6). This latter case was not taken from literature,
but was provided by the Cardiac Surgery Department of the
Catholic University of Leuven. Data refer to VAD implantation
and were acquired just during the implanting surgery at VAD
onset.
All data mentioned above were used to feed and to test the
Self-Tuning module; the results are reported in Table 5. Data in
brackets indicate the percentage difference between the simulated
data and the corresponding target data.
4. Discussion
Aim of the presented work is to develop a computational simu-
lator both for training and clinical use. This simulator is conceivedsys/dias(mean) [mmHg] PAP sys/dias(mean) [mmHg] PCW [mmHg]
80 (99) 27/6 (14) 6
8 (60) 43/29 (33) 28
2 (72) 47/35 (39) 35
1 (62) 48/34 (39) 34
sys/dias(mean) [mmHg] – DP PAP sys/dias(mean) [mmHg] PCW [mmHg]
7 (82) 35/17 (23) 16
4 (59) 46/32 (37) 32
4 (66) 43/28 (33) 28
6 (80) – DP = 42 38/21 (27) 20
sys/dias(mean) [mmHg] PAP sys/dias(mean) [mmHg] RAP [mmHg]
80 (99) 27/6 (14) 6
3 (77) 15/7 (9) 8
8 (58) 18/9 (12) 10
sys/dias(mean) [mmHg] PAP sys/dias(mean) [mmHg] PCW [mmHg]
4 (53) 49/36 (40) 36
0 (72) 39/23 (28) 23
8 (80) 35/18 (24) 18
0/91 30/11 (17) 10
sys/dias(mean) [mmHg] PAP sys/dias(mean) [mmHg] PCW [mmHg]
98 (120) 36/13 (21) 11
85 (105) 30/8 (16) 7
57 (78) 34/11 (18) 8
64 (86) 35/12 (19) 9
Table 4
Literature data used for the Self-Tuning module.
LIC [27] LDC [29] LDC [29]
CASE 1 CASE 2 CASE 3
HR [bpm] 72 91 100
AOP [mmHg] 77.7 89 77
AOPsys [mmHg] 113 – –
AOPdias [mmHg] 60 – –
LVes [cm3] 200 178 137
LVed [cm3] 266 217 167
CI [(l/min)/m2] 2.0 1.9 1.6
PCW [mmHg] 27 30 33
CO [l/min] 4.75 3.55 3.0
RAP [mmHg] – – –
PAP [mmHg] – – –
LDC [27] RVD [28] CircuLite
CASE 4 CASE 5 CASE 6
HR [bpm] 77 86 94
AOP [mmHg] 82.3 102 68
AOPsys [mmHg] 119 – 89
AOPdias [mmHg] 64 – 56
LVes [cm3] 218 – 147
LVed [cm3] 284 – 174
CI [(l/min)/m2] 1.9 – 2.5
PCW [mmHg] 30 12 9
CO [l/min] 5.08 3.49 4.4
RAP [mmHg] – 14 7
PAP [mmHg] – 60 7
Data refer to 5 different cases with a total of three different pathologies: Left
Ischemic Cardiomyopathy (LIC), Left Dilated Cardiomyopathy (LDC), Right
Ventricular Dysfunction (RVD). The sixth condition refers to a CircuLite
implantation.
Table 5
Data obtained from the Self-Tuning module.
CASE 1 CASE 2 CASE 3
HR [bpm] 72 (0.0) 91 (0.0) 100 (0.0)
AOP [mmHg] 76 (2.2) 92 (3.4) 73 (5.2)
AOPsys [mmHg] 101 (10.9) 101 (–) 80 (–)
AOPdias [mmHg] 55 (8.3) 83 (–) 67 (–)
LVes [cm3] 193 (3.5) 189 (6.2) 142 (3.6)
LVed [cm3] 256 (3.8) 230 (6.0) 171 (2.4)
CI [(l/min)/m2] 1.88 (6.0) 1.98 (4.1) 1.55 (3.3)
PCW [mmHg] 26 (3.7) 32 (6.7) 34 (3.0)
CO [l/min] 4.5 (5.3) 3.7 (4.2) 2.9 (3.3)
RAP [mmHg] 6 (–) 5 (–) 4 (–)
PAP [mmHg] 33 (–) 37 (–) 38 (–)
Emaxl [mmHg/cm3] 1.63 (–) 1.16 (–) 0.85 (–)
LV0 [cm3] 131 (–) 101 (–) 46 (–)
Edl [mmHg/cm3] 0.102 (–) 0.138 (–) 0.197 (–)
Emaxr [mmHg/cm3] 1.01 (–) 1.01 (–) 1.01 (–)
CASE 4 CASE 5 CASE 6
HR [bpm] 77 (0.0) 86 (0.0) 94 (0)
AOP [mmHg] 78 (5.2) 107 (4.9) 74 (8.8)
AOPsys [mmHg] 103 (13.4) 117 (–) 83 (6.7)
AOPdias [mmHg] 56 (12.5) 97 (–) 66 (17.9)
LVes [cm3] 209 (4.1) 62 (–) 142 (3.4)
LVed [cm3] 270 (4.9) 106 (–) 168 (3.4)
CI [(l/min)/m2] 1.76 (7.4) (–) 2.8 (10.6)
PCW [mmHg] 29 (3.3) 13 (8.3) 9 (0)
CO [l/min] 4.7 (7.5) 3.8 (8.9) 4.7 (6.8)
RAP [mmHg] 6 (–) 13 (7.1) 7 (0)
PAP [mmHg] 35 (–) 65 (8.3) 18 (5.9)
Emaxl [mmHg/cm3] 1.88 (–) 2.05 (–) 0.78 (–)
LV0 [cm3] 155 (–) 5 (–) 33 (–)
Edl [mmHg/cm3] 0.106 (–) 0.126 (–) 0.052 (–)
Emaxr [mmHg/cm3] 1.01 (–) 0.33 (–) 0.33 (–)
Results of Self-Tuning module that has been fed with the hemodynamic parameters
of Table 4. Data in brackets refer to the percentage error between the literature data
in Table 4 and the results of simulations.
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Using a 4th generation IntelREG Core i7-4702HQ processor and a
time step for equations solving of 0.002 s the execution time for
a heart cycle is 1 s.
The main user interface provides the hemodynamic data usu-
ally available on a cardio monitor (pressure waveforms and mean
values in a heart cycle) plus some other information (PV loops,
etc.).
As authors wanted to keep the main interface simple, some
modules were developed on different windows that can be opened
or closed according to the needs.
A special effort was devoted to the Self-Tuning interface as
authors tried to insert only data that are commonly used in the
clinical environment. That is to say that instead of ventricular elas-
tance or systemic resistance, the user will have to insert data like
mean pressures, mean ﬂow, ventricular volumes, etc. The transla-
tion between these clinical data into ‘‘simulator data’’ is automat-
ically done and hidden to the user thanks to the Self-Tuning
module. The user can specify the amount of input data to insert
by ticking from a predeﬁned list the types of measurements avail-
able for the speciﬁc patient to be simulated (see Fig. A2).
4.1. Training use
The training module is conceived as a tool able to offer an ‘‘in-
teractive’’ learning procedure. That is to say that the user can
autonomously select one or more diseases, simulate therapies,
make comparisons with other therapies and other diseases, try to
characterize a speciﬁc hemodynamic condition (see Random dis-
eases module).
As an example the simulator can facilitate the understanding of
how one or more diseases can change shape, dimension and posi-
tion of pressure volume loops on the PV plane and the hemody-
namic of a patient in toto. Then, the user can also simulate
different therapies and see possible improvements of patient’s con-
dition (especially in complex pathologies where the simultaneous
use of different therapies is likely).
Some examples of the implemented diseases for the left ventri-
cle are reported in Fig. 1, other hemodynamic results (i.e. AOP, CO,
etc.) are summarized in Table 3. In general, the decreasing of Emaxl
(conditions 2 and 3) provokes a shift of the PV loop to higher vol-
umes values and lower pressure values. To overcome this condition
the cardiovascular system reacts chronically by changing the ven-
tricular diastolic function (decrease of Edl) and increasing the sys-
temic peripheral resistance. Data of conditions 2 and 3 in Table 3
are in agreement with the ACCF/AHA guideline [30] associating
advanced heart failure with reduced EF% (630), a PCW > 16
mmHg and a RAP > 12 mmHg (estimated from PAP).
In addition, the effects of an increment of Edl are shown (condi-
tion 4), with the associated reduction of ventricular volumes, LVed
in particular. Such a condition is an example of hypertrophic car-
diomyopathy, a disease characterized by an increased left ventric-
ular thickness (P15 mm) associated with nondilated and stiffer
ventricular chambers [30].
The effects of ventricular valve diseases are shown in Fig. 2. The
implemented diseases concern mitral valve regurgitation, aortic
valve regurgitation and stenosis. Results show how the shape of
PV loops is strongly affected by valvular diseases. As for example
in case of valve regurgitation, the PV loop does not show an isovol-
umetric relaxation/contraction because of the blood volume
loss/increment through the leaking valve. An important parameter
for the evaluation of such a valvular disease is the regurgitation
fraction that corresponds to the percentage of blood that regurgi-
tates back through the aortic or mitral valve. In simulations 2
and 3 (see Fig. 2 and in Table 3) we reported an ischemic + dilated
cardiomyopathy with a regurgitation fraction of 56% in case of
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results are in agreement with [31], indicating, in the case of a sev-
ere chronic mitral or aortic insufﬁciency, a regurgitation frac-
tion > 50% and a left ventricular dilatation.
Condition 4 in Fig. 2 and Table 3 is an example of severe aortic
stenosis combined with a mild hypertrophic cardiomyopathy
(EF% = 60, DP = 42 mmHg). This simulation is in agreement the def-
inition of severe aortic stenosis characterized by a high pressure
drop across the aortic valve (DPP 40 mmHg) and usually associ-
ated with left ventricular hypertrophy [32].
In Fig. 3 the effects of the decrement of right ventricular
end-systolic elastance are shown, also combined with pulmonary
hypertension. The trends of right ventricular PV loops are much
similar to those illustrated for the left ventricle in Fig. 1.
In Fig. 4 some examples of VAD therapies are shown. As
starting hemodynamic condition (condition 1 in Fig. 4) we rep-
resented an advanced heart failure with an EF% 6 25 (that is
listed in the recommendation for mechanical circulatory support
[30]).
The user can select and activate different VADs in order to check
the speciﬁc reaction of the cardiovascular system. From Fig. 4 it is
evident how two pumps (Heart Ware and Heart Mate II), in apical
connection, provoke an unloading of the ventricle, by draining
blood from it. As a consequence, the PV loop assumes a
non-rectangular shape, with non isovolumetric ventricular
relaxation/contraction. In the case of the CircuLite Synergy
Micropump, in atrio–aortic connection, the blood is drained from
the left atrium. Therefore the PV loop keeps the typical rectangular
shape. For any type of assistance, the reduction of ventricular vol-
ume is evident, and the level of volume reduction depends on VAD
characteristics and on the speed set.
The other interventions that can be simulated are: drug infusion
and blood transfusion/loss. In Fig. 5 the effects of 3 lg/kg/min of
SNP are shown, consisting in a vasodilatation of peripheral resis-
tances with a consequent increment of ventricular stroke volume
and a reduction of ventricular pressure in systole. A different trend
is observed during blood volume transfusion, whose effects mainly
concern an increment of ventricular ﬁlling with a consequent
increment of LVed and of ventricular pressure. The model offers
also the possibility to study the combined effects of SNP infusion
and baroreﬂex control: the ﬁrst reducing blood pressure by vasodi-
lation, the second counteracting with vasoconstriction and by
increasing heart rate.
Some considerations need to be done concerning the choice of
parameters values for different types of diseases (Table 2). The
association of parameters values – level of severity is not very
immediate since most of pathologies are clinically classiﬁed on
the basis of patient’s perception and on individual physician’s
judgment (i.e. the NYHA classiﬁcation [33]). These data are only
indirectly linked with mere cardiovascular parameters. Moreover
a cardiovascular condition, especially in its chronic state, is usually
associated with a series of phenomena naturally occurring to com-
pensate the impaired patient’s hemodynamic status (i.e. ventricu-
lar remodeling, systemic/pulmonary hypertension, etc.). From a
simulation point of view this means that a speciﬁc disease is usu-
ally associated with the alteration of more than one parameter,
both ventricular and circulatory ones. Such a representation goes
beyond the aim of Pre-Set Diseases that is not to recreate a heart
failure condition in toto but to simulate the effects that a single
parameter can induce on the overall hemodynamic condition.
Such an approach permits to better visualize the link cause effect
of a single parameter on patients’ hemodynamics (an analysis dif-
ﬁcult to be performed in clinics). For the simulation of a more
likely chronic patient’s status, the user will have to select more
than one disease from the list as it was shown already in the results
section.4.2. Clinical use
The use of a cardiovascular simulator as a clinical tool is a
challenging and complex task that requires a strict cooperation
between model developers and clinicians (end users). The pre-
sent work is aimed at illustrating a model that is conceived for
clinical purposes and developed on the basis of clinical needs.
Its use in clinical practice is still not systematic but hopefully
will be in a near future. Nevertheless some examples of the clin-
ical use of the simulator and of how it can be easily adapted to
different clinical needs was already showed in previous works
[11,24,34].
The simulator is conceived as a tool able to provide additional
info to be integrated with other info the clinician has. The SDSS
is an example of how the simulator can be integrated into a wider
structure including intelligent data mining, statistical data, etc.
Such an approach, makes the simulator a component of the infor-
mation ﬂow chart that from a diagnosis leads to a therapy
administration.
In this frame, an important characteristic the simulator should
have is the ﬂexibility and the easiness in being adapted to different
hemodynamic conditions. The personalization of the simulator to
patients’ data is a crucial point to assure its clinical exploitability.
Therefore, special attention was given to this issue, developing a
dedicated module to tailor the simulator on single patient (see
below).
4.2.1. The Self-Tuning module
The tuning of a simulator to a speciﬁc hemodynamic condition
is a process that raises different issues as the lack of clinical data
and the translation of clinical measurements into model parame-
ters. The Self-Tuning module is aimed at overcoming these limita-
tions with an automatized procedure so that the user can insert
patient data, activate the Self-Tuning procedure and simulate a
speciﬁc patient’s hemodynamic autonomously. Such a tool might
encourage the use of the simulator in the clinical arena.
In this paper, the Self-Tuning module was tested on 6 different
conditions (CASE 1–6), 5 taken from literature, and 1 obtained from
a VAD implanted patient. These 6 cases have been used to test the
Self-Tuning module in different conditions, with left and right ven-
tricular failure, or during VAD assistance. Results, summarized in
Table 5, evidence a percentage error among target data and simu-
lated data lower than 10%, which correspond to the tolerance set
by the authors. The tolerance was set to 10%, as this value is a rea-
sonable estimation of the percentage error characterizing hemody-
namic measurements in clinics [35]. The only exceptions are
AOPsys and AOPdias errors that can assume higher values. In this
case probably a measurement of Tdecay (that in our case has been
only estimated according to Eq. (3)) would have led to a better
approximation of both variables.
Some considerations should be given to the choice of the target
data to be provided to the simulator. Some data are commonly and
easily measurable in clinic as: HR⁄, BodyWeight⁄, Height⁄, AOP⁄,
AOPsys⁄, AOPdias⁄. Some other data (LAP⁄, PAP⁄, RAP⁄) require inva-
sive measurements or electrographic and echocardiographic mea-
surements (Tdecay⁄, LVes⁄ and LVed⁄). These latter are less feasible
in clinical environment unless a patient undergoes a VAD implan-
tation surgery. To overcome this issue, the present Self-Tuning
module can be adapted to different sets of data: as example, if
PAP⁄ is not available, DPAP in Eq. (5) will be equal to zero and will
not affect any parameter tuning. Of course the quality and reliabil-
ity of the simulation will increase with the number of target data
inserted in CVS.
In the overall Self-Tuning module strategy, these target data are
used to set model parameters, in addition to speciﬁc relationship
taken from literature whenever possible (‘‘e.g.’’ Teicholz formula).
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procedure. These parameters, automatically changed, refer to left
ventricular condition (Emaxl, LV0), the right ventricular condition
(Emaxr, Edr) and to the total volume of blood (TOTVol). The choice
of tuning these parameters is due to different reasons:
 Emaxl and LV0 parameters are difﬁcult to be estimated in clinics
therefore after an initial setting a better tuning is necessary.
 Emaxr, Edr: the right ventricle is not that often investigated in
clinics. Therefore it is unlikely that right ventricular parameters
are measured.Cardio-
vascular 
model
Drugs
Infusion
VAD
Baroreflex 
module
Liquid 
transfusion
Fig. A1. Overall structure of the simulator. The main core of the system is the cardiov
therapeutic interventions are grouped (liquid infusion/withdrawal, drug administration,
to reproduce patient’s speciﬁc conditions, Pre-Set Diseases to reproduce one or more disea
reproduces randomly one or more diseases. In the most external level the interfaces of t
the simulator with patient’s speciﬁc data and the SDSS.
A 
B 
C D 
E F 
Fig. A2. The user interface of the simulator. Section A refers to systemic arterial pressu
refers to VAD ﬂow waveform, section C (D) refers to left (right) pressure – volume loop, s
control buttons, section G refers to Random diseases module, section H refers to predeﬁne
section K refers to blood transfusion, section L refers to model Self-Tuning (each input pa The total volume of blood is initially estimated using a relation-
ship taken from literature (see 3.9.1). Despite this, we know that
blood volume can vary according to the amount of liquid taken
by the patient. Therefore a further tuning is requested.
4.2.2. Specialist Decision Support System (SDSS)
The SDSS is an example of how the simulator can be integrated
into a wider structure aimed at supporting clinicians in the
treatment of VAD patients. The SDSS creates a hallmark in the ﬁeld,
supporting medical and VAD experts through the different phases
of VAD therapy [23,26]. Rather than addressing a single issue, theSelf-Tuning
Pre-set
diseases
SDSS
Data inputRandom 
diseases
ascular model. Then, in the second level the baroreﬂex model and all modules for
VAD). At the third level the running modalities are speciﬁed: Self-Tuning procedure
ses on demand and the Random diseases modality according to which the simulator
he simulator are listed: the hemodynamic data input developed for the user to feed
G 
H 
I J K 
L 
re, pulmonary arterial pressure and central venous pressure waveforms. Section B
ection E refers to hemodynamic data averaged on one heart cycle, section F refers to
d diseases module, section I refers to VADs, section J refers to Drug Infusion module,
rameter can be ticked or not according if the user has the measurement on patient).
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and expert-knowledge techniques, in order to effectively assess
and exploit real patient data, as well as simulated patient dataFig. A3. Block diagram of the Self-Tuning module. At ﬁrst the user inserts the input data
parameters during the Self-Tuning procedure (they are marked with the symbol ‘‘⁄’’). At S
on the reference parameters values (marked with subscript ‘‘ref’’, see Table 1). At STEP
TOTVol, Emaxl, Emaxr, Edr, LV0.for: treatment support and, in case, weaning of VAD, knowledge
discovery and statistics support derived from the collection of data
in time and their association with clinically relevant events,in the dedicated interface (see section L of Fig. A2). These data will be used as target
TEP 1 the cardiovascular parameters are calculated on the basis of the input data and
2 the recursive procedure is performed. In this phase the parameters adjusted are:
L. Fresiello et al. / Journal of Biomedical Informatics 57 (2015) 100–112 111suction and speed optimization support and ﬁnally selection of the
best VAD candidates on the basis of individual risk/beneﬁt proﬁles.5. Limitations
Concerning clinical applications it is important to specify that a
systematic use of the simulator in clinical practice is a task that
goes beyond the aim of the present work ant that will require fur-
ther efforts from both medical and engineering sides. The aim of
this work is to offer a new automatized methodology of model per-
sonalization and of model interface to other systems that might
encourage the use of simulators in the clinical arena.6. Conclusion
The proposed computational cardiovascular simulator is con-
ceived as a tool addressed to clinical applications. The core of the
CVS, made by a lumped parameters model, assures a low execution
time and a low model complexity. The modular structure permits
to include or exclude some modules according to users’ speciﬁc
needs thus contributing to keep the level of complexity to the min-
imum necessary.
Thanks to its structure, the present simulator is a valid tool for
both training and clinical uses. The ﬁrst application is devoted to
all clinicians and students that want to get an overall understand-
ing of the most common cardiovascular diseases, with the relative
effects of therapeutic interventions.
The second application is devoted to clinical arena where the
clinician can reproduce ‘‘virtually’’ the hemodynamic condition of
a speciﬁc patient. In this case, the simulator can be used to provide
a more detailed analysis of patient’s hemodynamics and to test dif-
ferent therapies.
According to what is stated above, the innovation of this simu-
lator stands in its structure and in the idea behind its exploitability.
The simulator structure permitted to collect and put together a
wide set of diseases, therapies and applications.Conﬂict of interest
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